The exploitation of GLUT overexpression in tumor cells and tissues, such as the glucose receptor GLUT1, has already been successfully harnessed in PET studies with fluorodeoxyglucose or [99mTc]-DTPA-DG [20–22] and has been used in MRI with Gd-DTPA-DG [9] and niosomes bearing glucose conjugates (N-palmitoyl glucosamine) [8]. Here, SLC2A1 is linked to neoplasm.